Napredna pretraga

Pregled bibliografske jedinice broj: 182941

HLA class I and II genes polymorphism in psoriatic patients


Pašić, Aida; Dražić, Vesna; Grahovac, Maja; Lipozenčić, Jasna; Dorić, Anka; Grahovac, Blaženka
HLA class I and II genes polymorphism in psoriatic patients // Fifth International Symposium on Molecular Diagnostics in Laboratory Medicine
Graz, 2004. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
HLA class I and II genes polymorphism in psoriatic patients

Autori
Pašić, Aida ; Dražić, Vesna ; Grahovac, Maja ; Lipozenčić, Jasna ; Dorić, Anka ; Grahovac, Blaženka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Fifth International Symposium on Molecular Diagnostics in Laboratory Medicine / - Graz, 2004

Skup
Fifth International Symposium on Molecular Diagnostics in Laboratory Medicine, 6-9-06. 2004.

Mjesto i datum
Graz, Austria, 6-9. 06. 2004

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Psoriasis; polymorphism of HLA class I and II; disease association; psoriasis guttata;

Sažetak
Psoriasis vulgaris (PV) is a chronic skin disease strongly associated with several susceptibility genes. Recent genome-wide linkage analyses have identified a PV susceptibility locus (PSOR1), which is part of HLA region (HLA-B/HLA-C) mapped on chromosome 6p21.3. The aim of the study was to identify the risk HLA alleles and haplotypes associated with various clinical forms of psoriasis. A total of 169 unrelated patients and 190 controls (unrelated healthy blood donors) mached by age and sex, were typed for HLA class I and II alleles using low resolution Biotest-SSP kits (Dreieich, Germany) and high resolution Dynal AllSet SSP (Dynal Biotech LTD, Bromborough, UK). Allele frequencies and probable haplotype associations were estimated by Arlequin, version 2000. Statistical analysis was performed using GraphPad Prism ver.3.00 for Windows, San Diego, Ca, USA. RESULTS: Statistical analysis showed the frequencies of all psoriatic risk alleles and haplotypes to be significantly increased as compared with the control group. In psoriasis type I (early onset, <40 yrs, with family occurence) the following risk HLA alleles were identified: B13 (OR=6.99), B57 (OR=14.60), Cw*06 (OR=14.90), DRB1*0701 (OR=6.08), DQA1*0201 (OR=4.16), DQB1*0303 (OR=13.98). In psoriasis type II ( late onset, >40 yrs, without family history), the frequency of HLA class I and II alleles did not differ significantly from that in the control group. The Croatian population of psoriasis type I patients were characterized by two extended risk haplotypes, B13-Cw*06-DRB1*0701-DQA1*0201-DQB1*0202 (EH 13.1) and B57-Cw*06-DRB1*0701-DQA1*0201-DQB1*0303 (EH 57.1) A significant frequency of EH 57.1 haplotype was found in the group of patients with familial occurrence of the disease , OR=18.2 ; 95% CI, 5.02-65.85 (p<0.001) and EH 13.1 haplotype in those without familial clustering of the disease, OR=14.68 ; 95% CI, 4.77-45.17 (p<0.001). The haplotypes recorded in patients with psoriasis type II did not differ significantly from those in the control group. Guttate psoriasis was found to be differeniated from other clinical forms of psoriasis by the significant presence of HLA allele B37 (OR=52.5 ; 95% CI, 5.8-474.2 ; p<0.001) as a specific marker. Although 55% of patients with guttate psoriasis had a positive family history, HLA allele B57 as a marker of the familial clustering of the disease was not significantly present in this clinical form of psoriasis.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Etnologija i antropologija